Clinical Trials & Research

Reviewed by Emily Henderson, B.Sc.Jul 20 2020 An interdisciplinary team from Frankfurt and Jena has developed a kind of bait with which to fish protein complexes out of mixtures. Thanks to this “bait”, the desired protein is available much faster for further examination in the electron microscope. The research team has christened this innovative layer

Print this page LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized

Jul 17 2020 From the moment a kidney becomes available, there are just 24 hours to identify the recipient and carry out the transplant. Waiting lists are extremely long, available organs are few and not all of them are ‘ideal’. Furthermore, a recipient has the ability to ‘refuse’ a kidney, for instance by continuing with

Print this page BOSTON, July 14, 2020 (GLOBE NEWSWIRE) —  Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first patient has been enrolled in the BOLD (Biliary atresia and the use of Odevixibat in treating Liver Disease) global Phase 3 clinical trial of odevixibat, a highly potent and selective

New research out of the Japan Advanced Institute of Science and Technology (JAIST) utilizes digital image analysis technology to shed light on some of the challenges children face when representing their imaginations through the medium of paint. The research also offers concrete insight into the development of children’s psyches, and importantly, offers suggestions for educators

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 14, 2020– Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New

First off, it’s in statute already in HIPAA that preexisting conditions are covered.” Health and Human Services Secretary Alex Azar, on July 9, speaking at a virtual summit sponsored by The Hill newspaper One of the most popular features of the Affordable Care Act is its guarantee of insurance coverage — at no greater cost

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 10, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir. The data are being presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual)

Acute ischemic strokes (AIS) associated with COVID-19 are more severe, lead to worse functional outcomes and are associated with higher mortality , according to new research published yesterday in Stroke, a journal of the American Stroke Association, a division of the American Heart Association. In “Characteristics and Outcomes in Patients with COVID-19 and Acute Ischemic

Print this page San Francisco, CA, July 8, 2020 — Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced it has initiated in Brazil a randomized, placebo-controlled Phase 2 proof-of-concept trial of ANG-3777 plus standard of care in

Jul 10 2020 Cochlear Limited, the global leader in implantable hearing solutions, today announced the U.S. Food and Drug Administration (FDA) approval of three new products to its suite of hearing technology solutions. Kanso 2 Sound Processor The approval of the CochlearTM Nucleus® Kanso® 2 Sound Processor, Nucleus® 7 Sound Processor for Nucleus 22 Implant

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 8, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19.

Chronic and recurrent bacterial diseases are treatment-resistant due to the ability of the pathogens to establish biofilms, which act as fortresses built of extracellular DNA and proteins to protect populations of the bacteria. For more than 11 years, researchers Lauren Bakaletz, PhD, and Steve Goodman, PhD, have been working to understand and dismantle biofilms. Biofilms

Print this page NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications

Asthma does not appear to increase the risk for a person contracting COVID-19 or influence its severity, according to a team of Rutgers researchers. Older age and conditions such as heart disease, high blood pressure, chronic obstructive pulmonary disease, diabetes and obesity are reported risk factors for the development and progression of COVID-19.” Reynold A.

Print this page PLYMOUTH MEETING, Pa., June 30, 2020 /PRNewswire/ – INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase

Reviewed by Emily Henderson, B.Sc.Jul 3 2020 Indian health experts say the findings of a US study — which suggest that population density is unrelated to COVID-19 infection rates — to be completely contradictory to their experience of dealing with the pandemic in India, a country with 1.3 billion people. Shima Hamidi, lead author of

Print this page NEW YORK & MAINZ, Germany–(BUSINESS WIRE)  July 01, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program

In sufferers of Parkinson’s disease, clumps of α-synuclein (alpha-synuclein), sometimes known as the ‘Parkinson’s protein’, are found in the brain. These destroy cell membranes, eventually resulting in cell death. Now, a new method developed at Chalmers University of Technology, Sweden, reveals how the composition of cell membranes seems to be a decisive factor for how

News Clinical Trials Recombinant Novel Coronavirus Vaccine (adenovirus type 5 Vector) Received Military Specially-Needed Drug Approval in China Print this page Hong Kong, June 29, 2020 — This announcement is made by CanSino Biologics Inc. (the “Company”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong

Women are significantly more likely to receive prescriptions of opioid analgesics. Read the study, which was performed in a nationally representative sample of adults in the U.S., in Journal of Women’s Health. Researchers from University of California Davis School of Medicine identified three main factors driving this discrepancy. These included lower, more adverse socio-economic status

Print this page NORTH CHICAGO, Ill., June 26, 2020 /PRNewswire/ – Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License

A new analysis of 16 years of publicly accessible health data on 68.5 million Medicare enrollees provides broad evidence that long-term exposure to fine particles in the air – even at levels below current EPA standards – leads to increased mortality rates among the elderly. Based on the results of five complementary statistical models, including

Print this page 24 June 2020 — Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).1 Compared

Tony Scott boarded an American Airlines flight May 25 from Los Angeles to Dallas. It was a trip he felt he had to take despite concerns about the coronavirus. His son, who lives in Texas, was having health problems. The teen seated next to Scott in business class wasn’t wearing a mask. Scott was surprised

Print this page MUMBAI, India, June 20, 2020 /PRNewswire/ — In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu®

In a heart attack, a series of biochemical processes leave the heart damaged, much like a car after an accident. There is loss of tissue that needs to be rebuilt, proteins that get crushed, muscle damage, and interruptions to blood and oxygen flow to the heart. Because the heart is not very good at repairing

Print this page June 20, 2020 — A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by the National Institutes of Health. A data and safety monitoring board (DSMB) met late Friday and determined that while there was no